

Enquiries: CPA

Ref: HP13-2022ARV

e-mail: cpapharma@health.gov.za

Cover Page for Contractual Price Adjustments for HP13-2022ARV CPA Period: 5.0 Active: 1 February 2025 Rates of Exchange: 6/3 Month

Currency	Base Average Rates of Exchange Average for the period 01 January 2021 to 30 June 2021	Previous CPA 4.1 Adjustment Rate (3 Month)	Period for calculating adjustment Rate of Exchange	Current CPA 5.0 Adjustme nt Rate (6 Month)	Current CPA 5.0 Adjustment Rate (3 Month)
Yuan	R2.25	R2.51		R2.50	R2.49
Indian Rupee	R0.20	R0.21	01 July 2024	R0.21	R0.21
Euro	R17.53	R19.75	to 31 December 2024	R19.42	R19.09
BR Pound	R20.19	R23.36		R23.15	R22.93
US Dollar	R14.54	R17.99		R17.93	R17.87

This Price Adjustment is reflected on Addendum 78 - 87 for HP13-2022ARV.

Jana 200 Dren

K JAMALOODIEN CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 78: ABBVIE (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following AbbVie (Pty) Ltd price, effective 1 February 2025.

Item No	Description	NSN	Current Price	Revised Price
28	LOPINAVIR 200mg, RITONAVIR 50mg film coated tablet, 112 tablets	181896251	R327.03	R325.16

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Janasoodien

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA

Ref: HP13-2022ARV

e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 79: ADCOCK INGRAM HEALTHCARE (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Adcock Ingram Healthcare (Pty) Ltd prices, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
22	EFAVIRENZ 50mg capsule, 28 capsules	181896194	R18.96	R18.92
25	LAMIVUDINE 10mg/ml oral solution, 240ml bottle with syringe top and a calibrated oral dosage syringe	180205026	R22.34	R22.29
26	LAMIVUDINE 150mg scored tablet, 56 tablets	181896198	R32.30	R32.15
32	NEVIRAPINE 200mg tablet, 56 tablets	181922275	R40.79	R40.59
41	TENOFOVIR 300mg tablet, 28 tablets	181896242	R40.11	R39.94
46	ZIDOVUDINE 300mg tablet, 56 tablets	181896243	R85.48	R85.03
48	ZIDOVUDINE 50mg/5ml syrup, 200ml bottle with syringe top and a calibrated 10ml oral dosage syringe	180165395	R33.07	R33.00

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Yours faithfully Lanaroo Sren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 80: AUROBINDO PHARMA (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Aurobindo Pharma (Pty) Ltd prices, effective 1 February 2025

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
6	ATAZANAVIR 200mg tablet/capsule, 56/60 tablets/capsules	181872915	R365.96	R363.80
7	ATAZANAVIR 300mg tablet/capsule, 28/30 tablets/capsules	222001277	R257.48	R255.96
12	DARUNAVIR 600mg tablet, 56 tablets	181922274	R840.20	R835.15
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R88.06	R87.56
25	LAMIVUDINE 10mg/ml oral solution, 240ml bottle with syringe top and a calibrated oral dosage syringe	180205026	R29.12	R28.96
34	NEVIRAPINE 50mg/5ml suspension, 240ml bottle with syringe top and a 2 ml calibrated oral dosage syringe	180387396	R33.72	R33.53

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

HP13-2022ARV: ADDENDUM 80: AUROBINDO PHARMA (PTY) LTD - PRICE ADJUSTMENT

& Janaroo Sien

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: <u>cpapharma@health.gov.za</u>

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 81: CIPLA MEDPRO SA (PTY) LTD T/A CIPLA MEDPRO MANUFACTURING (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Cipla Medpro SA (Pty) Ltd t/a Cipla Medpro Manufacturing (Pty) Ltd prices, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
1	ABACAVIR 120 mg, LAMIVUDINE 60 mg dispersible tablet, 28/30 tablets	222001210	R56.44	R56.11
19	DOLUTEGRAVIR 50mg, ABACAVIR 600mg, LAMIVUDINE 300mg tablet, 28/30 tablets	222000210	R253.39	R252.10
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R88.29	R87.86
30	LOPINAVIR 40mg, RITONAVIR 10mg capsule, 120 capsules	222000968	R253.64	R252.22
33	NEVIRAPINE 50mg/5ml suspension, 100ml bottle with syringe top and a 2 ml calibrated oral dosage syringe	181871672	R20.73	R20.61

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Janaroo Tren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 82: EMCURE PHARMACEUTICALS SA (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Emcure Pharmaceuticals SA (Pty) Ltd price, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
19	DOLUTEGRAVIR 50mg, ABACAVIR 600mg, LAMIVUDINE 300mg tablet, 28/30 tablets	222000210	R179.05	R178.01

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

& Janasoo Tren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 83: HETERO DRUGS SA (PTY) LTD - PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Hetero Drugs SA (Pty) Ltd prices, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
2	ABACAVIR 20mg/ml oral solution, 240ml bottle with syringe top and a calibrated oral dosage syringe	181781208	R71.73	R71.29
4	ABACAVIR 600mg and LAMIVUDINE 300mg tablet, 28 tablets	181900960	R126.74	R125.94
18	DOLUTEGRAVIR 50mg tablet, 30 tablets	181936065	R25.40	R25.24
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R72.86	R72.39
38	RITONAVIR 100mg tablet, 60 tablets	222001256	R89.67	R89.11
42	TENOFOVIR 300mg, EMTRICITABINE 200mg tablet, 28 tablets	181896252	R57.96	R57.59
43	TENOFOVIR 300mg, EMTRICITABINE 200mg, EFAVIRENZ 600mg tablet, 28/30 tablets	181896256	R95.79	R95.18
44	TENOFOVIR 300mg, EMTRICITABINE 200mg, EFAVIRENZ 600mg tablet, 84/90 tablets	222001249	R273.00	R271.25
47	ZIDOVUDINE 300mg, LAMIVUDINE 150mg tablet, 56 tablets	181896255	R94.75	R94.14

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

& Janasoo Fren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: <u>cpapharma@health.gov.za</u>

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 84: INNOVATA PHARMACEUTICALS (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Innovata Pharmaceuticals (Pty) Ltd price, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
8	ATAZANAVIR 300mg, RITONAVIR 100mg tablet, 28/30 tablets	222001257	R243.08	R241.71

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

& Janasoo Fren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 85: PHARMACARE LIMITED – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Pharmacare Limited prices, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
2	ABACAVIR 20mg/ml oral solution, 240ml bottle with syringe top and a calibrated oral dosage syringe	181781208	R71.73	R71.46
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R76.04	R75.73
23	EFAVIRENZ 600mg tablet, 28 tablets	181896196	R55.87	R55.64
43	TENOFOVIR 300mg, EMTRICITABINE 200mg, EFAVIRENZ 600mg tablet, 28/30 tablets	181896256	R93.83	R93.35

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Janaroo Fren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: <u>cpapharma@health.gov.za</u>

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2025

ADDENDUM 86: SONKE PHARMACEUTICALS (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Sonke Pharmaceuticals (Pty) Ltd prices, effective 1 February 2025.

ITEM NO	DESCRIPTION	NSN	CURRENT PRICE	REVISED PRICE
17	DOLUTEGRAVIR 50mg scored tablet, 28/30 tablets	222000208	R46.16	R45.97
18	DOLUTEGRAVIR 50mg tablet, 30 tablets	181936065	R40.73	R40.56
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R89.48	R89.03
21	EFAVIRENZ 200mg capsule, 84 capsules	181922255	R64.77	R64.38
26	LAMIVUDINE 150mg scored tablet, 56 tablets	181896198	R37.16	R36.95
42	TENOFOVIR 300mg, EMTRICITABINE 200mg tablet, 28 tablets	181896252	R71.83	R71.45

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

ana100 den

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025



Enquiries: CPA Ref: HP13-2022ARV e-mail: <u>cpapharma@health.gov.za</u>

CONTRACT NUMBER HP13-2022ARV: SUPPLY AND DELIVERY OF ANTI-RETROVIRAL MEDICINES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2022 TO 30 JUNE 2025

ADDENDUM 87: VIATRIS HEALTHCARE (PTY) LTD – PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Viatris Healthcare (Pty) Ltd prices, effective 1 February 2025.

Item No	Description	NSN	Current Price	Revised Price
1	ABACAVIR 120 mg, LAMIVUDINE 60 mg dispersible tablet, 28/30 tablets	222001210	R53.46	R49.22
3	ABACAVIR 300mg tablet, 56 tablets	181896191	R112.02	R104.20
4	ABACAVIR 600mg and LAMIVUDINE 300mg tablet, 28 tablets	181900960	R125.34	R116.59
5	ABACAVIR 60mg dispersable/crushable tablet, 56 tablets	181901076	R42.70	R39.31
10	DARUNAVIR 400mg, RITONAVIR 50mg tablet, 56/60 tablets	222001314	R431.63	R397.40
18	DOLUTEGRAVIR 50mg tablet, 30 tablets	181936065	R24.69	R22.70
20	DOLUTEGRAVIR 50mg, LAMIVUDINE 300mg, TENOFOVIR 300mg tablet, 28/30 tablets	222000207	R69.24	R63.64
21	EFAVIRENZ 200mg capsule, 84 capsules	181922255	R52.33	R48.10
23	EFAVIRENZ 600mg tablet, 28 tablets	181896196	R41.53	R38.17
27	LOPINAVIR 100mg and RITONAVIR 25mg film coated tablet, 56 tablets	181922256	R75.16	R69.09
28	LOPINAVIR 200mg, RITONAVIR 50mg film coated tablet, 112 tablets	181896251	R275.91	R253.60
42	TENOFOVIR 300mg, EMTRICITABINE 200mg tablet, 28 tablets	181896252	R60.62	R56.53
43	TENOFOVIR 300mg, EMTRICITABINE 200mg, EFAVIRENZ 600mg tablet, 28/30 tablets	181896256	R89.55	R83.51

HP13-2022ARV: ADDENDUM 87: VIATRIS HEALTHCARE (PTY) LTD – PRICE ADJUSTMENT

Item No	Description	NSN	Current Price	Revised Price
44	TENOFOVIR 300mg, EMTRICITABINE 200mg, EFAVIRENZ 600mg tablet, 84/90 tablets	222001249	R287.57	R268.18
45	ZIDOVUDINE 100mg capsule, 100 capsules	181922278	R61.68	R56.79
47	ZIDOVUDINE 300mg, LAMIVUDINE 150mg tablet, 56 tablets	181896255	R95.90	R88.29

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

& Janasoo Fren

K JAMALOODIEN CHIEF-DIRECTOR: SECTOR WIDE PROCUREMENT DATE: 24 January 2025